Seth Lederman Purchases 5,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman acquired 5,000 shares of the stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $11.79 per share, with a total value of $58,950.00. Following the purchase, the chief executive officer directly owned 9,005 shares of the company’s stock, valued at $106,168.95. The trade was a 124.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Seth Lederman also recently made the following trade(s):

• On Wednesday, March 18th, Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock. The shares were bought at an average price of $14.89 per share, with a total value of $223,350.00.

Tonix Pharmaceuticals Trading Down 2.1%

NASDAQ:TNXP traded down $0.25 during trading hours on Tuesday, reaching $11.46. 544,959 shares of the company traded hands, compared to its average volume of 425,927. The business’s 50-day moving average price is $13.20 and its two-hundred day moving average price is $15.06. The stock has a market capitalization of $182.68 million, a P/E ratio of -0.80 and a beta of 1.67. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $10.87 and a 1 year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The company had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.13 million. As a group, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new stake in Tonix Pharmaceuticals during the second quarter valued at about $25,000. Strs Ohio grew its holdings in Tonix Pharmaceuticals by 9.9% during the fourth quarter. Strs Ohio now owns 7,800 shares of the company’s stock valued at $122,000 after purchasing an additional 700 shares during the period. Rhumbline Advisers grew its holdings in Tonix Pharmaceuticals by 8.0% during the third quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock valued at $295,000 after purchasing an additional 908 shares during the period. Bank of America Corp DE grew its holdings in Tonix Pharmaceuticals by 32.7% during the third quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock valued at $112,000 after purchasing an additional 1,146 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in Tonix Pharmaceuticals during the third quarter valued at about $29,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wall Street Zen cut Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. Finally, TD Cowen upgraded Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tonix Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $22.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.